First Quarter Financial Report

15. May 2018 | 2 min read

Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include
  • Record level for total operating revenue of MNOK 11.2 for the quarter
  • 100 % growth in sales revenue compared to 1Q17
  • 24 % growth in sales revenue compared to 4Q17
  • Strong sales for both Cystatin C and fCal
  • New Proof-of-Concept announced post end of quarter

Please find the report enclosed. The report will also be made available on www.gentian.com.

 
For further information, please contact:
Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
 
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525
 
 
MeldingsID:  451378
 
 

You may also read


May 29, 2026 - Ole Sørlie

Mandatory notification of trade

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

Read more

May 13, 2026 - Ole Sørlie

Flaggemelding – Gentian Diagnostics ASA

Melding etter verdipapirhandelloven § 4-2 Oslo, 13 mai 2026 Vatne Capital AS, kontrollert av Runar Vatne, har..

Read more

May 13, 2026 - Ole Sørlie

Board resignation

Moss, 13 May 2026 Reference is made to the stock exchange release regarding Vatne Capital’s notification of..

Read more